全文获取类型
收费全文 | 2805篇 |
免费 | 213篇 |
出版年
2023年 | 18篇 |
2022年 | 39篇 |
2021年 | 85篇 |
2020年 | 52篇 |
2019年 | 59篇 |
2018年 | 82篇 |
2017年 | 54篇 |
2016年 | 110篇 |
2015年 | 164篇 |
2014年 | 216篇 |
2013年 | 225篇 |
2012年 | 268篇 |
2011年 | 252篇 |
2010年 | 159篇 |
2009年 | 139篇 |
2008年 | 174篇 |
2007年 | 157篇 |
2006年 | 120篇 |
2005年 | 124篇 |
2004年 | 94篇 |
2003年 | 89篇 |
2002年 | 75篇 |
2001年 | 22篇 |
2000年 | 25篇 |
1999年 | 20篇 |
1998年 | 17篇 |
1997年 | 11篇 |
1996年 | 5篇 |
1995年 | 6篇 |
1994年 | 6篇 |
1993年 | 7篇 |
1992年 | 8篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 10篇 |
1988年 | 6篇 |
1987年 | 15篇 |
1985年 | 5篇 |
1984年 | 8篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 3篇 |
1975年 | 8篇 |
1974年 | 5篇 |
1973年 | 8篇 |
1972年 | 3篇 |
排序方式: 共有3018条查询结果,搜索用时 31 毫秒
91.
Bärbel Ulmer Cathrin Hagenlocher Silke Schmalholz Sabrina Kurz Axel Schweickert Ayelet Kohl Lee Roth Dalit Sela-Donenfeld Martin Blum 《Cell reports》2013,3(3):615-621
- Download : Download full-size image
92.
93.
Laura?Quotti Tubi Carmela?GurrieriEmail author Alessandra?Brancalion Laura?Bonaldi Roberta?Bertorelle Sabrina?Manni Laura?Pavan Federica?Lessi Renato?Zambello Livio?Trentin Fausto?Adami Maria?Ruzzene Lorenzo?A?Pinna Gianpietro?SemenzatoEmail author Francesco?Piazza 《Journal of hematology & oncology》2013,6(1):78
Background
The involvement of protein kinase CK2 in sustaining cancer cell survival could have implications also in the resistance to conventional and unconventional therapies. Moreover, CK2 role in blood tumors is rapidly emerging and this kinase has been recognized as a potential therapeutic target. Phase I clinical trials with the oral small ATP-competitive CK2 inhibitor CX-4945 are currently ongoing in solid tumors and multiple myeloma.Methods
We have analyzed the expression of CK2 in acute myeloid leukemia and its function in cell growth and in the response to the chemotherapeutic agent daunorubicin We employed acute myeloid leukemia cell lines and primary blasts from patients grouped according to the European LeukemiaNet risk classification. Cell survival, apoptosis and sensitivity to daunorubicin were assessed by different means. p53-dependent CK2-inhibition-induced apoptosis was investigated in p53 wild-type and mutant cells.Results
CK2α was found highly expressed in the majority of samples across the different acute myeloid leukemia prognostic subgroups as compared to normal CD34+ hematopoietic and bone marrow cells. Inhibition of CK2 with CX-4945, K27 or siRNAs caused a p53-dependent acute myeloid leukemia cell apoptosis. CK2 inhibition was associated with a synergistic increase of the cytotoxic effects of daunorubicin. Baseline and daunorubicin-induced STAT3 activation was hampered upon CK2 blockade.Conclusions
These results suggest that CK2 is over expressed across the different acute myeloid leukemia subsets and acts as an important regulator of acute myeloid leukemia cell survival. CK2 negative regulation of the protein levels of tumor suppressor p53 and activation of the STAT3 anti-apoptotic pathway might antagonize apoptosis and could be involved in acute myeloid leukemia cell resistance to daunorubicin.94.
Christian Milani Arancha Hevia Elena Foroni Sabrina Duranti Francesca Turroni Gabriele Andrea Lugli Borja Sanchez Rebeca Martín Miguel Gueimonde Douwe van Sinderen Abelardo Margolles Marco Ventura 《PloS one》2013,8(7)
Assessing the distribution of 16S rRNA gene sequences within a biological sample represents the current state-of-the-art for determination of human gut microbiota composition. Advances in dissecting the microbial biodiversity of this ecosystem have very much been dependent on the development of novel high-throughput DNA sequencing technologies, like the Ion Torrent. However, the precise representation of this bacterial community may be affected by the protocols used for DNA extraction as well as by the PCR primers employed in the amplification reaction. Here, we describe an optimized protocol for 16S rRNA gene-based profiling of the fecal microbiota. 相似文献
95.
Xiao L. Moore Danielle Michell Sabrina Lee Michael R. Skilton Rajesh Nair John B. Dixon Anthony M. Dart Jaye Chin-Dusting 《PloS one》2013,8(1)
Carotid intima-media-thickness (cIMT) and carotid distensibility (distensibility), structural and functional properties of carotid arteries respectively, are early markers, as well as strong predictors of cardiovascular disease (CVD). The characteristic of these two parameters in individuals with BMI>40.0 kg/m2 (Class III obesity), however, are largely unknown. The present study was designed to document cIMT and distensibility in this population and to relate these to other factors with established association with CVD in obesity. The study included 96 subjects (65 with BMI>40.0 kg/m2 and 31, age- and gender-matched, with BMI of 18.5 to 30.0 kg/m2). cIMT and distensibility were measured by non-invasive high resolution ultrasonography, circulatory CD133+/KDR+ angiogenic cells and endothelial microparticles (EMP) by flow cytometry, and plasma levels of adipokines, growth factors and cytokines by Luminex immunoassay kits. The study results demonstrated increased cIMT (0.62±0.11 mm vs. 0.54±0.08 mm, P = 0.0002) and reduced distensibility (22.52±10.79 10−3kpa−1
vs. 29.91±12.37 10−3kpa−1, P<0.05) in individuals with BMI>40.0 kg/m2. Both cIMT and distensibility were significantly associated with traditional CVD risk factors, adiposity/adipokines and inflammatory markers but had no association with circulating angiogenic cells. We also demonstrated, for the first time, elevated plasma EMP levels in individuals with BMI>40.0 kg/m2. In conclusion, cIMT is increased and distensibility reduced in Class III obesity with the changes predominantly related to conventional CVD risk factors present in this condition, demonstrating that both cIMT and distensibility remain as CVD markers in Class III obesity. 相似文献
96.
97.
Socioeconomic status and anthropometric changes—A meta‐analytic approach from seven German cohorts
下载免费PDF全文
![点击此处可从《Obesity (Silver Spring, Md.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Johannes Haerting Saskia Hartwig Daniel Tiller Daniel Medenwald Susanne Vogt Barbara Thorand Rolf Holle Ursula Bachlechner Heiner Boeing Benedikt Merz Ute Nöthlings Sabrina Schlesinger Sabine Schipf Till Ittermann Nicole Aumann Anja Schienkiewitz Marjolein Haftenberger Karin H. Greiser Jasmine Neamat‐Allah Verena Katzke Alexander Kluttig 《Obesity (Silver Spring, Md.)》2016,24(3):710-718
98.
Angiopoietin‐2, its soluble receptor Tie‐2, and metabolic syndrome components in a population‐based sample
下载免费PDF全文
![点击此处可从《Obesity (Silver Spring, Md.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
99.
Lindsay B. Avery Mengmeng Wang Mania S. Kavosi Alison Joyce Jeffrey C. Kurz Yao-Yun Fan 《MABS-AUSTIN》2016,8(6):1064-1078
Therapeutic antibodies continue to develop as an emerging drug class, with a need for preclinical tools to better predict in vivo characteristics. Transgenic mice expressing human neonatal Fc receptor (hFcRn) have potential as a preclinical pharmacokinetic (PK) model to project human PK of monoclonal antibodies (mAbs). Using a panel of 27 mAbs with a broad PK range, we sought to characterize and establish utility of this preclinical animal model and provide guidance for its application in drug development of mAbs. This set of mAbs was administered to both hemizygous and homozygous hFcRn transgenic mice (Tg32) at a single intravenous dose, and PK parameters were derived. Higher hFcRn protein tissue expression was confirmed by liquid chromatography-high resolution tandem mass spectrometry in Tg32 homozygous versus hemizygous mice. Clearance (CL) was calculated using non-compartmental analysis and correlations were assessed to historical data in wild-type mouse, non-human primate (NHP), and human. Results show that mAb CL in hFcRn Tg32 homozygous mouse correlate with human (r2 = 0.83, r = 0.91, p < 0.01) better than NHP (r2 = 0.67, r = 0.82, p < 0.01) for this dataset. Applying simple allometric scaling using an empirically derived best-fit exponent of 0.93 enabled the prediction of human CL from the Tg32 homozygous mouse within 2-fold error for 100% of mAbs tested. Implementing the Tg32 homozygous mouse model in discovery and preclinical drug development to predict human CL may result in an overall decreased usage of monkeys for PK studies, enhancement of the early selection of lead molecules, and ultimately a decrease in the time for a drug candidate to reach the clinic. 相似文献